The interventional tumor ablation market size has grown strongly in recent years. It will grow from $1.77 billion in 2025 to $1.93 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to rising global cancer incidence, advancement of medical imaging technologies, increasing preference for minimally invasive therapies, expansion of interventional oncology practices, improved clinical outcomes of ablation procedures.
The interventional tumor ablation market size is expected to see strong growth in the next few years. It will grow to $2.66 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing integration of ai-assisted imaging guidance, rising adoption of personalized cancer treatment, expansion of ambulatory surgical centers, growing investments in oncology device innovation, increasing demand for cost-effective cancer therapies. Major trends in the forecast period include increasing adoption of minimally invasive tumor ablation procedures, rising use of image-guided ablation technologies, expansion of microwave and radiofrequency ablation systems, growing demand for outpatient cancer treatments, enhanced focus on precision oncology.
The increasing incidence of cancer is expected to drive the growth of the interventional tumor ablation market in the coming years. Cancer encompasses a group of diseases marked by the uncontrolled growth and spread of abnormal cells, which can invade surrounding tissues and spread to other parts of the body through the blood and lymphatic systems. The rising occurrence of cancer is largely attributed to lifestyle and environmental factors, including smoking, unhealthy diets, obesity, and exposure to carcinogenic substances. Interventional tumor ablation supports cancer treatment by providing minimally invasive therapeutic options that serve as alternatives to conventional surgery. These techniques shorten treatment durations and recovery times by enabling precise tumor destruction, thereby improving patient outcomes and quality of life. For instance, in February 2024, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, more than 35 million new cancer cases are projected globally by 2025, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the rising incidence of cancer is contributing to the expansion of the interventional tumor ablation market.
Leading companies operating in the interventional tumor ablation market are concentrating on the development of advanced technological solutions, such as BioTrace software suites, to improve procedural accuracy and enhance treatment effectiveness. BioTrace software suites are integrated platforms designed to track, manage, and analyze biological and clinical data, particularly within healthcare and research settings. For example, in July 2024, TechsoMed Medical Technologies Ltd., an Israel-based medical device manufacturer, introduced BioTraceIO Vision and BioTraceIO Precision, software solutions developed for image-guided liver tumor ablation therapy. BioTraceIO Vision utilizes artificial intelligence-driven personalized treatment planning and assessment tools based on standard medical imaging to increase the precision and efficiency of liver tumor ablation. BioTraceIO Precision offers real-time ultrasound-based visualization and predictive mapping of the ablation zone during and after procedures, enabling clinicians to evaluate tissue damage and treatment outcomes with strong correlation to 24-hour post-ablation computed tomography scans.
In February 2024, Immunophotonics Inc., a US-based biotechnology company, entered into a partnership with AngioDynamics Inc. This collaboration is intended to combine Immunophotonics’ lead immunotherapy candidate, IP-001, with AngioDynamics’ ablation technologies to investigate the potential of integrating ablation with immunotherapy for the treatment of solid tumor cancers. AngioDynamics Inc. is a US-based medical device company that provides microwave and radiofrequency ablation systems for minimally invasive cancer therapies.
Major companies operating in the interventional tumor ablation market are Johnson & Johnson, Medtronic plc, Siemens Healthineers AG, Stryker Corporation, Boston Scientific Corporation, Olympus Corporation, Terumo Corporation, EDAP TMS S.A., Elekta AB, AngioDynamics Inc., InSightec Ltd., Cascination AG, IceCure Medical Ltd., Theraclion SA, Mermaid Medical Group A/S, H.S. Hospital Service S.p.A., Varian Medical Systems Inc., Neuwave Medical, BTG plc, MedWaves Inc., Perseon Medical AB, Chongqing Haifu Medical Technology Co. Ltd., AngioDynamics Nanoknife Division, Galil Medical Inc.
North America was the largest region in the interventional tumor ablation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interventional tumor ablation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the interventional tumor ablation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the interventional tumor ablation market by increasing costs of imported ablation probes, imaging systems, electronic control units, and specialized medical components used in rfa, mwa, cryoablation, and hifu systems. Hospitals and cancer centers in North America and Europe are most affected due to reliance on imported high-end medical devices, while Asia-Pacific faces cost pressure on device exports. These tariffs are increasing capital expenditure and slowing equipment replacement cycles. However, they are also encouraging local manufacturing, regional device assembly, and innovation in cost-optimized ablation technologies.
The interventional tumor ablation market research report is one of a series of new reports that provides interventional tumor ablation market statistics, including interventional tumor ablation industry global market size, regional shares, competitors with a interventional tumor ablation market share, detailed interventional tumor ablation market segments, market trends and opportunities, and any further data you may need to thrive in the interventional tumor ablation industry. This interventional tumor ablation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Interventional tumor ablation is a minimally invasive procedure that utilizes image-guided techniques to target and destroy cancerous or benign tumors without the need for open surgery. It uses thermal or non-thermal energy to eliminate tumor cells while minimizing damage to surrounding healthy tissue. This procedure is often employed when surgery is not viable or as an alternative to traditional treatments.
The main product types in interventional tumor ablation include open surgery, minimally invasive surgery, and image-guided interventions. Open surgery involves making an incision in the body to access and treat the affected area, typically using scalpels and other instruments. Key technologies in this field include radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, laser ablation, and high-intensity focused ultrasound (HIFU). Device types used in these procedures include ablation systems, consumables, support devices, and imaging systems. Tumor ablation is frequently applied to liver, kidney, lung, and bone tumors. The end users of these technologies range from hospitals and specialized cancer treatment centers to ambulatory surgical centers and research institutes.
The interventional tumor ablation market consists of revenues earned by entities by providing services such as electroporation, tumor biopsy services, thermal ablation monitoring, and post-ablation follow-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. The interventional tumor ablation market also includes sales of radiofrequency ablation (RFA) generators, microwave ablation (MWA) systems, cryoablation probes, laser fibers and electrode needles. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The interventional tumor ablation market size is expected to see strong growth in the next few years. It will grow to $2.66 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing integration of ai-assisted imaging guidance, rising adoption of personalized cancer treatment, expansion of ambulatory surgical centers, growing investments in oncology device innovation, increasing demand for cost-effective cancer therapies. Major trends in the forecast period include increasing adoption of minimally invasive tumor ablation procedures, rising use of image-guided ablation technologies, expansion of microwave and radiofrequency ablation systems, growing demand for outpatient cancer treatments, enhanced focus on precision oncology.
The increasing incidence of cancer is expected to drive the growth of the interventional tumor ablation market in the coming years. Cancer encompasses a group of diseases marked by the uncontrolled growth and spread of abnormal cells, which can invade surrounding tissues and spread to other parts of the body through the blood and lymphatic systems. The rising occurrence of cancer is largely attributed to lifestyle and environmental factors, including smoking, unhealthy diets, obesity, and exposure to carcinogenic substances. Interventional tumor ablation supports cancer treatment by providing minimally invasive therapeutic options that serve as alternatives to conventional surgery. These techniques shorten treatment durations and recovery times by enabling precise tumor destruction, thereby improving patient outcomes and quality of life. For instance, in February 2024, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, more than 35 million new cancer cases are projected globally by 2025, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the rising incidence of cancer is contributing to the expansion of the interventional tumor ablation market.
Leading companies operating in the interventional tumor ablation market are concentrating on the development of advanced technological solutions, such as BioTrace software suites, to improve procedural accuracy and enhance treatment effectiveness. BioTrace software suites are integrated platforms designed to track, manage, and analyze biological and clinical data, particularly within healthcare and research settings. For example, in July 2024, TechsoMed Medical Technologies Ltd., an Israel-based medical device manufacturer, introduced BioTraceIO Vision and BioTraceIO Precision, software solutions developed for image-guided liver tumor ablation therapy. BioTraceIO Vision utilizes artificial intelligence-driven personalized treatment planning and assessment tools based on standard medical imaging to increase the precision and efficiency of liver tumor ablation. BioTraceIO Precision offers real-time ultrasound-based visualization and predictive mapping of the ablation zone during and after procedures, enabling clinicians to evaluate tissue damage and treatment outcomes with strong correlation to 24-hour post-ablation computed tomography scans.
In February 2024, Immunophotonics Inc., a US-based biotechnology company, entered into a partnership with AngioDynamics Inc. This collaboration is intended to combine Immunophotonics’ lead immunotherapy candidate, IP-001, with AngioDynamics’ ablation technologies to investigate the potential of integrating ablation with immunotherapy for the treatment of solid tumor cancers. AngioDynamics Inc. is a US-based medical device company that provides microwave and radiofrequency ablation systems for minimally invasive cancer therapies.
Major companies operating in the interventional tumor ablation market are Johnson & Johnson, Medtronic plc, Siemens Healthineers AG, Stryker Corporation, Boston Scientific Corporation, Olympus Corporation, Terumo Corporation, EDAP TMS S.A., Elekta AB, AngioDynamics Inc., InSightec Ltd., Cascination AG, IceCure Medical Ltd., Theraclion SA, Mermaid Medical Group A/S, H.S. Hospital Service S.p.A., Varian Medical Systems Inc., Neuwave Medical, BTG plc, MedWaves Inc., Perseon Medical AB, Chongqing Haifu Medical Technology Co. Ltd., AngioDynamics Nanoknife Division, Galil Medical Inc.
North America was the largest region in the interventional tumor ablation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interventional tumor ablation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the interventional tumor ablation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the interventional tumor ablation market by increasing costs of imported ablation probes, imaging systems, electronic control units, and specialized medical components used in rfa, mwa, cryoablation, and hifu systems. Hospitals and cancer centers in North America and Europe are most affected due to reliance on imported high-end medical devices, while Asia-Pacific faces cost pressure on device exports. These tariffs are increasing capital expenditure and slowing equipment replacement cycles. However, they are also encouraging local manufacturing, regional device assembly, and innovation in cost-optimized ablation technologies.
The interventional tumor ablation market research report is one of a series of new reports that provides interventional tumor ablation market statistics, including interventional tumor ablation industry global market size, regional shares, competitors with a interventional tumor ablation market share, detailed interventional tumor ablation market segments, market trends and opportunities, and any further data you may need to thrive in the interventional tumor ablation industry. This interventional tumor ablation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Interventional tumor ablation is a minimally invasive procedure that utilizes image-guided techniques to target and destroy cancerous or benign tumors without the need for open surgery. It uses thermal or non-thermal energy to eliminate tumor cells while minimizing damage to surrounding healthy tissue. This procedure is often employed when surgery is not viable or as an alternative to traditional treatments.
The main product types in interventional tumor ablation include open surgery, minimally invasive surgery, and image-guided interventions. Open surgery involves making an incision in the body to access and treat the affected area, typically using scalpels and other instruments. Key technologies in this field include radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, laser ablation, and high-intensity focused ultrasound (HIFU). Device types used in these procedures include ablation systems, consumables, support devices, and imaging systems. Tumor ablation is frequently applied to liver, kidney, lung, and bone tumors. The end users of these technologies range from hospitals and specialized cancer treatment centers to ambulatory surgical centers and research institutes.
The interventional tumor ablation market consists of revenues earned by entities by providing services such as electroporation, tumor biopsy services, thermal ablation monitoring, and post-ablation follow-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. The interventional tumor ablation market also includes sales of radiofrequency ablation (RFA) generators, microwave ablation (MWA) systems, cryoablation probes, laser fibers and electrode needles. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Interventional Tumor Ablation Market Characteristics
3. Interventional Tumor Ablation Market Supply Chain Analysis
4. Global Interventional Tumor Ablation Market Trends and Strategies
5. Interventional Tumor Ablation Market Analysis of End Use Industries
7. Global Interventional Tumor Ablation Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Interventional Tumor Ablation Total Addressable Market (TAM) Analysis for the Market
9. Interventional Tumor Ablation Market Segmentation
10. Interventional Tumor Ablation Market Regional and Country Analysis
11. Asia-Pacific Interventional Tumor Ablation Market
12. China Interventional Tumor Ablation Market
13. India Interventional Tumor Ablation Market
14. Japan Interventional Tumor Ablation Market
15. Australia Interventional Tumor Ablation Market
16. Indonesia Interventional Tumor Ablation Market
17. South Korea Interventional Tumor Ablation Market
18. Taiwan Interventional Tumor Ablation Market
19. South East Asia Interventional Tumor Ablation Market
20. Western Europe Interventional Tumor Ablation Market
21. UK Interventional Tumor Ablation Market
22. Germany Interventional Tumor Ablation Market
23. France Interventional Tumor Ablation Market
24. Italy Interventional Tumor Ablation Market
25. Spain Interventional Tumor Ablation Market
26. Eastern Europe Interventional Tumor Ablation Market
27. Russia Interventional Tumor Ablation Market
28. North America Interventional Tumor Ablation Market
29. USA Interventional Tumor Ablation Market
30. Canada Interventional Tumor Ablation Market
31. South America Interventional Tumor Ablation Market
32. Brazil Interventional Tumor Ablation Market
33. Middle East Interventional Tumor Ablation Market
34. Africa Interventional Tumor Ablation Market
36. Interventional Tumor Ablation Market Competitive Landscape and Company Profiles
37. Interventional Tumor Ablation Market Other Major and Innovative Companies
40. Interventional Tumor Ablation Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Interventional Tumor Ablation Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses interventional tumor ablation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for interventional tumor ablation? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The interventional tumor ablation market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Procedure Type: Minimally Invasive Surgery; Image-Guided Interventions2) By Technology: Radiofrequency Ablation (RFA); Microwave Ablation (MWA); Cryoablation; Laser Ablation; High-Intensity Focused Ultrasound (HIFU)
3) By Device Type: Ablation Systems; Consumables; Support Devices; Imaging Systems
4) By Application Area: Liver Tumors; Kidney Tumors; Lung Tumors; Bone Tumors
5) By End User: Hospitals; Specialized Cancer Treatment Centers; Ambulatory Surgical Centers; Research Institutes
Subsegments:
1) By Minimally Invasive Surgery: Percutaneous Tumor Ablation; Endoscopic Ablation2) By Image-Guided Interventions: Computed Tomography-Guided Tumor Ablation; Magnetic Resonance Imaging-Guided Tumor Ablation; Ultrasound-Guided Tumor Ablation
Companies Mentioned: Johnson & Johnson; Medtronic plc; Siemens Healthineers AG; Stryker Corporation; Boston Scientific Corporation; Olympus Corporation; Terumo Corporation; EDAP TMS S.A.; Elekta AB; AngioDynamics Inc.; InSightec Ltd.; Cascination AG; IceCure Medical Ltd.; Theraclion SA; Mermaid Medical Group A/S; H.S. Hospital Service S.p.A.; Varian Medical Systems Inc.; Neuwave Medical; BTG plc; MedWaves Inc.; Perseon Medical AB; Chongqing Haifu Medical Technology Co. Ltd.; AngioDynamics Nanoknife Division; Galil Medical Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Interventional Tumor Ablation market report include:- Johnson & Johnson
- Medtronic plc
- Siemens Healthineers AG
- Stryker Corporation
- Boston Scientific Corporation
- Olympus Corporation
- Terumo Corporation
- EDAP TMS S.A.
- Elekta AB
- AngioDynamics Inc.
- InSightec Ltd.
- Cascination AG
- IceCure Medical Ltd.
- Theraclion SA
- Mermaid Medical Group A/S
- H.S. Hospital Service S.p.A.
- Varian Medical Systems Inc.
- Neuwave Medical
- BTG plc
- MedWaves Inc.
- Perseon Medical AB
- Chongqing Haifu Medical Technology Co. Ltd.
- AngioDynamics Nanoknife Division
- Galil Medical Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.93 Billion |
| Forecasted Market Value ( USD | $ 2.66 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
